Cargando…

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration

PURPOSE: To evaluate the anatomical and functional outcomes in patients with submacular hemorrhage (SMH) due to age-related macular degeneration (AMD) treated with ranibizumab, and to evaluate the potential role of the SMH location in the final outcome after treatment. METHODS: Participants in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Karagiannis, Dimitrios, Chatziralli, Irini, Kaprinis, Konstantinos, Georgalas, Ilias, Parikakis, Efstratios, Mitropoulos, Panagiotis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679569/
https://www.ncbi.nlm.nih.gov/pubmed/29138543
http://dx.doi.org/10.2147/CIA.S145893
_version_ 1783277601481031680
author Karagiannis, Dimitrios
Chatziralli, Irini
Kaprinis, Konstantinos
Georgalas, Ilias
Parikakis, Efstratios
Mitropoulos, Panagiotis
author_facet Karagiannis, Dimitrios
Chatziralli, Irini
Kaprinis, Konstantinos
Georgalas, Ilias
Parikakis, Efstratios
Mitropoulos, Panagiotis
author_sort Karagiannis, Dimitrios
collection PubMed
description PURPOSE: To evaluate the anatomical and functional outcomes in patients with submacular hemorrhage (SMH) due to age-related macular degeneration (AMD) treated with ranibizumab, and to evaluate the potential role of the SMH location in the final outcome after treatment. METHODS: Participants in this study were 12 treatment-naïve patients with SMH due to neovascular AMD who were treated with intravitreal ranibizumab and had at least 12 months’ follow-up. All patients underwent best-corrected visual acuity measurement and optical coherence tomography at baseline and at every visit posttreatment, while fluorescein angiography was done at baseline and at the discretion of the physician thereafter. RESULTS: Of the patients, 83.4% showed improvement or stabilization in best-corrected visual acuity after treatment at the 12-month follow-up, with a mean number of 7.3±2.9 injections. Patients with SMH surrounding the foveal area in 360° presented worse anatomical and functional outcomes compared to those with SMH adjacent to the fovea. CONCLUSION: Intravitreal ranibizumab seems to be safe and effective, either improving or stabilizing visual acuity, in patients with SMH due to wet AMD. The location of the SMH may predict the final outcome after treatment.
format Online
Article
Text
id pubmed-5679569
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56795692017-11-14 Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration Karagiannis, Dimitrios Chatziralli, Irini Kaprinis, Konstantinos Georgalas, Ilias Parikakis, Efstratios Mitropoulos, Panagiotis Clin Interv Aging Original Research PURPOSE: To evaluate the anatomical and functional outcomes in patients with submacular hemorrhage (SMH) due to age-related macular degeneration (AMD) treated with ranibizumab, and to evaluate the potential role of the SMH location in the final outcome after treatment. METHODS: Participants in this study were 12 treatment-naïve patients with SMH due to neovascular AMD who were treated with intravitreal ranibizumab and had at least 12 months’ follow-up. All patients underwent best-corrected visual acuity measurement and optical coherence tomography at baseline and at every visit posttreatment, while fluorescein angiography was done at baseline and at the discretion of the physician thereafter. RESULTS: Of the patients, 83.4% showed improvement or stabilization in best-corrected visual acuity after treatment at the 12-month follow-up, with a mean number of 7.3±2.9 injections. Patients with SMH surrounding the foveal area in 360° presented worse anatomical and functional outcomes compared to those with SMH adjacent to the fovea. CONCLUSION: Intravitreal ranibizumab seems to be safe and effective, either improving or stabilizing visual acuity, in patients with SMH due to wet AMD. The location of the SMH may predict the final outcome after treatment. Dove Medical Press 2017-11-03 /pmc/articles/PMC5679569/ /pubmed/29138543 http://dx.doi.org/10.2147/CIA.S145893 Text en © 2017 Karagiannis et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Karagiannis, Dimitrios
Chatziralli, Irini
Kaprinis, Konstantinos
Georgalas, Ilias
Parikakis, Efstratios
Mitropoulos, Panagiotis
Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
title Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
title_full Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
title_fullStr Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
title_full_unstemmed Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
title_short Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
title_sort location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679569/
https://www.ncbi.nlm.nih.gov/pubmed/29138543
http://dx.doi.org/10.2147/CIA.S145893
work_keys_str_mv AT karagiannisdimitrios locationofsubmacularhemorrhageasapredictorofvisualoutcomeafterintravitrealranibizumabforagerelatedmaculardegeneration
AT chatziralliirini locationofsubmacularhemorrhageasapredictorofvisualoutcomeafterintravitrealranibizumabforagerelatedmaculardegeneration
AT kapriniskonstantinos locationofsubmacularhemorrhageasapredictorofvisualoutcomeafterintravitrealranibizumabforagerelatedmaculardegeneration
AT georgalasilias locationofsubmacularhemorrhageasapredictorofvisualoutcomeafterintravitrealranibizumabforagerelatedmaculardegeneration
AT parikakisefstratios locationofsubmacularhemorrhageasapredictorofvisualoutcomeafterintravitrealranibizumabforagerelatedmaculardegeneration
AT mitropoulospanagiotis locationofsubmacularhemorrhageasapredictorofvisualoutcomeafterintravitrealranibizumabforagerelatedmaculardegeneration